Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing’s disease trial
Lundbeck is exploring a new area in neurohormonal dysfunctions by initiating a phase II trial using Lu AG13909 as a potential treatment for Cushing’s disease. This marks an important step in Lundbeck’s commitment to advancing promising scientific innovations.H. Lundbeck A/S (Lundbeck) is enhancing its research and development in neurohormonal dysfunctions. A key part of this strategy is the development of Lu AG13909, a first-in-class monoclonal antibody (mAb) that targets the adrenocorticotropic hormone (ACTH). By binding to ACTH with high affinity, Lu AG13909 aims to reduce elevated